Brief: GenSight Biologics Submits EU Marketing Authorisation Application For LUMEVOQ Gene Therapy

Gensight Biologics SA

15/09/2020 06:36

Sept 15 (Reuters) - GENSIGHT BIOLOGICS SA  SIGHT.PA :
    * GENSIGHT BIOLOGICS SUBMITS EU MARKETING AUTHORISATION
APPLICATION FOR LUMEVOQ® GENE THERAPY TO TREAT VISION LOSS DUE
TO LEBER HEREDITARY OPTIC NEUROPATHY (LHON)
    * EMA DECISION EXPECTED IN H2 2021
    * U.S. FDA SUBMISSION ON TRACK FOR H2 2021
    * FIRST MARKETING AUTHORISATION APPLICATION FOR A GENE
THERAPY
TREATING A MITOCHONDRIAL DISEASE

Source text for Eikon:  ID:nBw5zDkD8a 
Further company coverage:  SIGHT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))